Pro-Pharmaceuticals Appoints Mildred Christian to Board of Directors.Business Editors/Health & Medical Writers NEWTON, Mass.--(BUSINESS WIRE)--Oct. 7, 2002 Expert on experimental design and government compliance to serve multiple roles with firm Pro-Pharmaceuticals Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :PROH PROH Prohibit PROH Propyl Alcohol ), a developer of molecular techniques to enhance the delivery and effectiveness of proven anti-cancer drugs, today announced the appointment of Mildred S. Christian, Ph.D., to its Board of Directors. Her addition brings Board membership to eight. Currently executive director of research for the Argus Research division of Charles River Charles River River, eastern Massachusetts, U.S. The longest river wholly in the state, it flows into Boston Bay after a course of about 80 mi (130 km). Navigable for about 7 mi (11 km), its estuary separates the cities of Boston and Cambridge. Laboratories, Dr. Christian, has been affiliated with Pro-Pharmaceuticals since its inception. She presently serves on the company's Scientific Advisory Board and has advised the firm on a number of business and scientific areas since its establishment in 2000. In her role at Argus, Dr. Christian is the top executive responsible for designing, evaluating and supervising scientific studies to ensure they are in accordance with government regulations and sponsors' requirements. At Argus, a Horsham, Pa.-based firm she founded in 1979, she has monitored, supervised or participated in various phases of more than 1400 developmental, reproductive and general toxicology evaluations. She also serves as executive director of science and compliance for Charles River Labs' Discovery and Development Services, with responsibility for scientific integrity and regulatory compliance on a corporate-wide basis. Dr. Christian received a doctorate from Thomas Jefferson University It began as Jefferson Medical College in 1824. On July 1, 1969 the institution officially became Thomas Jefferson University. The university is made up of three colleges:
n. The study of the structural changes of an individual from fertilization to adulthood. and pharmacology. She also holds degrees in zoology zoology, branch of biology concerned with the study of animal life. From earliest times animals have been vitally important to man; cave art demonstrates the practical and mystical significance animals held for prehistoric man. from the Pennsylvania State University Pennsylvania State University, main campus at University Park, State College; land-grant and state supported; coeducational; chartered 1855, opened 1859 as Farmers' High School. . "It gives me great pleasure to announce Mildred's election to the Board," said David Platt
"I am pleased to be expanding my role with Pro-Pharmaceuticals," Dr. Christian said. "I believe my 35 years of experience in drug development and regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: Pro-Pharmaceuticals is gearing up for Phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of its DAVANAT-1 drug formulation, approved by the Food and Drug Administration earlier this year. Research to date with DAVANAT-1 demonstrates its ability to enhance an anti-cancer drug's effectiveness while reducing its toxicity. The trial will evaluate a widely used treatment -- 5-Fluorouracil (5-FU) with and without DAVANAT enhancement -- against a late-stage cancer occurring in the digestive system (metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colorectal adenocarcinoma adenocarcinoma: see neoplasm. ). Pro-Pharmaceuticals Inc. -- Advancing Drugs Through Glycoscience(TM) Pro-Pharmaceuticals is a drug development company commercializing a new generation of anti-cancer treatments using carbohydrate molecules to significantly upgrade the safety and efficacy of standard cancer agents. Trading under the symbol PROH.OB, the company is headquartered in Newton, Mass., and was founded in 2000. Additional information is available at www.pro-pharmaceuticals.com. FORWARD LOOKING STATEMENTS: Any statements in this press release about future expectations, plans and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements. A number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: uncertainties regarding the Company's ability to obtain anticipated funding from private and public sources, to successfully develop, manufacture and market commercial products, and to secure anticipated orders; the risk that a robust market may not develop for the Company's products; the risk that strategic alliances and other contracts may be terminated; the risk that certain technologies utilized by the company will infringe intellectual property rights of others; competition encountered by the Company from firms around the globe; the amount and timing of the Company's future cash requirements and the availability of satisfactory financing sources. Reference is made to these and other factors discussed in the "Plan of Operations" section of the Company's most recent quarterly or annual report filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. While the Company anticipates that subsequent events and developments may cause the Company's views to change, the Company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date this press release is issued. Note to Editors: DAVANAT, DAVANAT-1 and "Advancing Drugs Through Glycoscience" are trademarks of Pro-Pharmaceuticals Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion